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Abstract
Background: High risk (HR) human papilloma Virus (HPV) genotypes have been associated with cervical cancer.
In Tanzania there is a limited data on the epidemiology of HPV and genotypes distribution among HIV infected
women. Here we document varieties of HPV genotypes associated with cervical squamous intraepithelial lesions
(SIL) among HIV- infected women at Bugando Medical Centre, Mwanza-Tanzania.
Methods: A cross sectional hospital based study involving HIV infected women was conducted between August
and October, 2014. Exfoliated cells from ectocervix and endocervix were collected using cytobrush. HPV genotypes
were detected using polymerase chain reaction (PCR) followed by sequencing using specific primers targeting
broad range of HPV types. Cytology was done to establish squamous intraepithelial lesions. Log binomial regression
analysis was done to establish risk ratios (RR) associated with HPV infection using STATA version 11.
Results: A total of 255 HIV infected women with mean age 39.2 ± 9.1 years were enrolled in the study. HPV DNA
was detected in 138/255 (54.1 %, 95 % CI: 47-60) of HIV infected women. Twenty six genotypes were detected in
various combinations; of these 17(65.3 %) were of HR genotypes. HR genotypes were detected in 124(48.6 %) of
HIV infected women. Common HR genotypes detected were HPV-52(26), HPV-58(21), HPV-35(20) and HPV-16(14).
The risk of being HPV positive was significantly higher among women with CD4 counts <100 (RR: 1.20, 95 % CI:
1.05-1.35, P = 0.006) and women with SIL (RR: 1.37, 95 % CI: 1.11-1.68, P = 0.005)
Conclusion: Significant proportion of HIV infected women with low CD4 counts have various grades of cervical SIL
associated with varieties of uncommon HR genotypes. There is a need to evaluate the effectiveness of the current
vaccine in preventing cervical cancer in developing countries where HIV is endemic.
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Background
Human papillomavirus (HPV) is a very common sexually
transmitted infection which is acquired through body fluids
and skin-to-skin contact [1]. It has been known as the
causal agent of cervical cancer [2]. In sub-Saharan Africa,
the incidence of cervical cancer has reached up to 40.7
cases per 100,000 women and it is the second cause of
death among cancers affecting women [3, 4]. In HIV in-
fected women the risk of acquiring HPV is even higher due
to immune suppression caused by HIV infection which has
the same epidemiological pattern as HPV in sub-Saharan
Africa [5, 6]. In most of these cases infection with multiple
genotypes has been found to predominate [5, 7–13].
Using molecular techniques, different HPV genotypes
have been identified and categorized as high risk (HR)
genotypes that are considered to be carcinogenic. These
include HPV- 16, 18, 31, 33, 35, 95, 45, 51, 52, 56, 58,
59, 68, 73 and 82; and are considered to cause approxi-
mately 95 % of cervical cancers [14]. Human papilloma
virus genotypes 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81,
and cp 6108 have been classified as low risk (LR); major-
ity of these have been found to cause genital warts [15].
Vaccines for HPV are available in some countries and
have been found to be effective in reducing infection
and its associated consequences [16].
As reported earlier in Africa, women particularly those
who are HIV infected are under-represented in the glo-
bal estimate of HPV genotypes [17]. This necessitates
the need to emphasize HPV screening programs for un-
derstanding its epidemiology and effective control. Here
we document varieties of HPV genotypes associated with
cervical squamous intraepithelial lesions (SIL) and asso-
ciated factors among HIV- infected women at Bugando
Medical Centre, Mwanza-Tanzania underscoring the im-
portance of focused control strategies to prevent cervical
cancer in developing countries.
Methods
Study design, site and population
A cross sectional hospital based study involving 255 HIV
infected women was conducted between August and Oc-
tober, 2014 at Bugando Medical Centre (BMC) HIV care
and treatment clinic (CTC). The clinic attends patients
who are on antiretroviral therapy (ART) and those who
have not started ART. The CTC provides routine Papa-
nicolaou (PAP) smear and gynaecological services with
no routine screening of HPV. An average of 80 revisiting
HIV infected women are seen per day [18].
Patient selection, socio-demographic and clinical information
The study included all HIV infected women aged >18 years
attending the CTC during the study period while excluding
women who underwent wedge resection of the cervix and
those with missed CD4 counts within 3 months of
specimen collection. Socio-demographic and relevant clin-
ical information collected were number of sexual partners,
parity, marital status, age at 1st sexual debut, history of STI,
history of genital warts, contraceptive use, and CD4 counts.
Sample collection and Laboratory procedures
Cervical exfoliated cells from the ectocervix and endo-
cervix were obtained using cytobrush; there after the tip
of the cytobrush was placed into a transport medium
and stored at -10 °C until processing. Papanicolaou
(PAP) smear was also taken, processed and interpreted
based on the revised 2001 Bethesda system [19].
Detection of HPV DNA
After vigorous vortexing of transport media, cytobrush
was removed and 200 μl of sample was used for nucleic
acid extraction with the MagNaPure LC DNA Large
Volume Kit on a MagNaPure LC instrument (Roche
Diagnostics, Mannheim, Germany) with elution volume
set at 100 μl. For the detection of HPV DNA, two differ-
ent end-point PCR assays (GEN-1 and GEN-2) were
done as previously described [20]. Both assays were done
using primers targeting sequences which are conserved
among a broad range of HPV genotypes, including all
major genital HPV genotypes (Tables 1 and 2). These
primers amplify fragments of approximately 460 bp for
GEN-1 and 220 bp for GEN-2. All PCR products were
sequenced (Eurofins Genomics, Ebersberg, Germany);
for sequencing of the GEN-1 PCR products, only primer
CP4 was used, whereas for GEN-2 PCR products both
PPF1 and PPR2 primers were used as previously described
[20]. After editing the sequence files using Vector NTI
Advance 9 software (Life Technologies, Darmstadt,
Germany), sequences were subjected to BLAST search
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to identify the
HPV genotypes. The efficiency of nucleic acid extraction
was controlled by a real-time PCR assay from our routine
diagnostics simultaneously targeting human cytomegalo-
virus (HCMV) and the human albumin gene.




CP4 5´-ATG GTA CAR TGG GCA
TWT GA-3´
HPV E1 (nt 1942-1961)
CP5 5´-GAG GYT GCA ACC AAA
AMT GRC-3´
HPV E1 (nt 2400-2378)
HPV GEN2 PCR
PPF1 5´-AAC AAT GTG TAG ACA
TTA TAA ACG AGC-3´
HPVE1 (nt 2082-2108)
PPR2 5´-ATT AAA CTC ATT CCA
AAA TAT GA-3´
HPVE1 (nt 2336-2314)
Numbering is according to the sequence of HPV16W12E (GenbankIDNr. AF125673)
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Data analysis
The data were entered in the computer using Microsoft
excel software and analysed using STATA version
11(STATA Corp LP, USA). Continuous variables were
summarized as mean with standard deviation or as median
with interquartile range whilst categorical variables were
summarized as proportions. Socioeconomic status (SES)
was defined using education, employment and business
status of the participant. Log binomial regression for esti-
mation of relative risk ratios was done followed by log
multinomial regression analysis for the factors with P value
of <0.2. Cross tabulation was done to detect variables with
collinearity. Factors found with collinearity were not sub-
jected into log multinomial regression analysis. The chi
square test and fisher’s exact test were done to compare
the distribution of HPV genotypes and SIL. Women with
mixed genotypes were regarded as having HR genotype if
HR genotype was present. Level of significance was mea-
sured by p-value whereby factors with p-values of less than
0.05 were considered statistically significant.
Results
Sociodemographic and obstetric characteristics
The mean age of enrolled women was 39.2 ± 9.14 years.
A total of 111(43.5 %) were married and 46 (18.03 %)
and 209(81.7 %) had higher and lower education respect-
ively. Majority of the enrolled women 138(54.1 %) had
Table 2 Socio-demographic & Reproductive characteristics of
the study population
Characteristics Frequency/mean/median Percentage (%)













≥ 1 child 231 90.6
Level of education
Lower level 209 81.7
High level 46 18.3
CD4 cells/μl
> 200 134 52.6
200-100 99 38.8
< 100 22 8.6
Age at first intercourse
Below 18 181 71.0










≤ 6 months 23 9.0
> 6 months 208 81.6
amean, bmedian
Table 3 Genotypes distribution of HPV
HPV genotypes Frequency LR/HR
HPV 6 1 LR
HPV 16 14 HR
HPV 18 8 HR
HPV 31 9 HR
HPV 33 4 HR
HPV 34 1 HR
HPV 35 20 HR
HPV 40 2 LR
HPV 42 5 LR
HPV 45 10 HR
HPV 47 1 LR
HPV 51 3 HR
HPV 52 26 HR
HPV 53 5 HR
HPV 54 2 LR
HPV 56 5 LR
HPV 58 21 HR
HPV 59 3 HR
HPV 66 5 HR
HPV 68 2 HR
HPV 73 1 HR
HPV 74 1 LR
HPV 82 4 HR
HPV 83 3 LR
HPV 90 3 LR
HPV 103 1 Unclassified
Total 160
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high socioeconomic status. A total of 158(61.9 %) were
residing in rural areas (Table 3).
Prevalence of HPV
Of the 255 enrolled women, 138 (54.1 %, 95 % CI: 47-
60) were found to have HPV DNA in their cervical cells.
Out of 138 HPV infected women; 124 (48.6 %) were
found to be infected with HR genotypes.
Genotypes distribution
In 138 HPV infected women; 26 genotypes were detected
in various combinations. A total of 17/138(12.3 %) of HIV
infected women had multiple HR genotypes. Of 26 geno-
types, 17(65.4 %; 95%CI: 44.7-81.2) were HR while 9
(34.6 %, 95%CI: 14-49) were LR genotypes (p = 0.028).
High risk genotypes detected were 16, 18, 31, 33, 34, 35,
45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82 whereas LR ge-
notypes detected were 6, 40, 42, 47, 54, 74, 83 and 90. The
total frequency of the genotypes detected was 160
(Table 4); of these common HR genotypes were HPV-
52(26, 16.3 %), HPV-58 (21, 13.1 %), HPV-35(20, 12.5 %)
and HPV-16(14, 8.8 %).
Cervical squamous intraepithelial lesions (SIL) and
genotypes distribution
Out of the 255 women; 91(35.6 %) had SIL on cyto-
logical studies. Of 91 HIV infected women with SIL, 74
(81.3 %) had low grade SIL whilst 17(18.7 %) had high
grade SIL. Eleven (64.7 %) of women with high grade
SIL had positive HPV DNA in their cervical cells.
Amongst these eleven women none-16 and non-18 ge-
notypes were detected in 9(81.8 %) of them. Out of 124
women infected with HR genotypes, 55 (44.4 %) had any
kind of SIL compared to only 31 (26.3 %) of 118 women
with no HPV infection (P = 0.003) Fig. 1. Non-significant
association between LR genotypes and SIL (5/14 vs. 31/118,
P = 0.264) was observed. Of 17 women with multiple high
risk genotypes, 1(5.8 %) had high grade SIL, 9(52.9 %) had
low grade SIL and 7(41.2 %) had no SIL.
Factors associated with HPV positivity among HIV
infected women
On log binomial regression analysis; women with
good socioeconomic status, low CD4 counts, use of
ARV ≤6 months and presence of SIL significant high
risk of HPV infection as shown in Table 4. Only women
with low CD4 counts (RR: 1.2, 95 % CI: 1.05-1.35, P =
0.006) and presence of SIL (RR: 1.37, 95 % CI: 1.11-1.68,
P = 0.005) remained with significant higher risk of being
infected with HPV on log multinomial regression analysis.
Discussion
Infection with oncogenic or HR human papillomavirus
(HPV) genotypes is the major cause of cervical cancer.
With the introduction of the quadrivalent HPV vaccine
which prevents four HPV types: HPV 16 and 18, as well
as HPV 6 and 11, that cause 90 % of genital warts the
knowledge concerning the distribution of HPV geno-
types has become increasingly public health concern
[21]. This study for the first time in Mwanza, Tanzania;
Fig. 1 High risk and low risk HPV genotypes in relation to cervical squamous intraepithelial lesions
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documents high proportion of HIV infected women car-
rying varieties of HR genotypes similarly to previous re-
ports [6, 22, 23]. As in previous studies [24], a
significant proportion of women were uncommonly
infected with multiple HR genotypes. These findings are
in agreement with previous studies which reported
uncommon HR genotypes infecting HIV infected
women in developing countries [4, 22, 25, 26]. This calls
for the need to include uncommon high risk genotypes
in the current vaccine production especially for areas
where HIV is endemic. The recently introduced a 9
valent (nanovalent) vaccine which includes HPV 52, 58,
45[27]; the commonest genotypes detected in this study
is of great advancement especially in sub Saharan Africa
where HIV is endemic. The World health organization
(WHO) should consider advocating replacing the
Table 4 Log binomial and log multinomial regression analysis on the factors associated with HPV positivity among HIV infected
women
Characteristics HPV positivity % Log binomial RR(95 % CI) p value Log multinomial RR(95 % CI) p-value
Age
> 45 (59) 25(42.4 %) 1
≤ 45 (196) 113(57.6 %) 1.3 (.98- 1.87) 0.06 1.26(0.89-1.4) 0.266
Residence
Rural(158) 85(53.8 %) 1
Urban(97) 53(54.64 %) 1.01(0.80-1.28) 0.896
SES
Low(117) 54(46.2 %) 1
High (138) 84(60.9 %) 1.31(1.04-1.67) 0.022 1.24(0.97-1.56) 0.064
H/STI
NO (213) 111(52.11 %) 1
YES (42) 27(64.29 %) 1.23(0.95-1.599) 0.113 1.15(098-1.6) 0.061
Parity
Nullporous (24) 14 (58.33 %) 1
≥ 1 child (231) 124 (53.68 %) 0.92(0.64-1.32) 0.650
CD4
> 200 (134) 67(50.00 %) 1
200-100(99) 54(54.55 %) 1.09(0.85-1.39) 0.490
< 100 (22) 17(77.27 %) 1.54(1.16-2.05) 0.003 1.20(1.05-1.35) 0.006
Age at first intercourse
Below 18 (181) 96(53.04 %) 1
Above 18 (74) 42(56.76 %) 1.07(0.84-1.36) 0.582
Marital status
Not married (144) 76(52.78 %) 1
Married (111) 62(55.86 %) 1.05(0.84-1.32) 0.623
aARV use
> 6 months(208) 117(51.44 %) 1
≤ 6 months(23) 16(69.5 %) 1.28 (1.00-1.036) 0.049
SIL
Absent (164) 78(47.5 %) 1
Present (91) 60(65.9 %) 1.49(1.18-1.87) 0.001 1.37(1.11-1.68) 0.005
Contraceptive use
None (164) 87(53.5 %) 1
Hormonal (62) 32 (51.6 %) 0.9729(0.73-1.288) 0.848
Condom(29) 19 (65.5 %) 1.23(0.914-1.66) 0.219
aARV use was not subjected into multivariate analysis because of its collinearity with CD4 counts,
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current quadrivalent vaccine which is available in many
centers in developing countries with nanovalent vaccine.
One of the interesting findings in this study is the pres-
ence of HPV 35 genotype in relative high frequency
which has been also found in other African countries
[22, 26, 28]. Unexpectedly, the recent introduced nano-
valent vaccine does not include HPV 35 genotype
emphasing the need to use epidemiological data for
future vaccine development.
Variation of HPV genotypes can occur even within the
country which might have implication in vaccine efficacy
in the same country. As evidenced by the fact that in the
current study, HPV-16 was not the commonest genotype
among women with high grade SIL while in the previous
study in Tanzania among HIV and non HIV infected
women HPV-16 was the commonest genotype among
women with high grade SIL [12]. There is a possibility
that the current existing HPV vaccines might have
diverse efficacy especially in developing countries.
The current study confirms the clear association be-
tween HPV infection and SIL. As in previous studies
[29–31], it was observed that women infected with HR
genotypes were more likely to have SIL than non-
infected and those infected with LR genotypes. Though
none of the women with LR genotypes had high grade
SIL; it was observed that 35.7 % of women infected with
LR genotypes had low grade SIL, following these women
over time to determine cervical changes and acquisition
of other genotypes will provide important information
regarding the role of LR genotypes and SIL. In addition,
women with low CD4 counts (<100) had significantly
higher risk of acquiring HPV infection (low and high
risk genotypes) as compared to their counterparts. Our
findings are similar to what have been reported earlier
[11, 32–34]. This is due to immune suppression which
poses the risk of opportunistic infections including HPV.
The major limitation of this study is inability to per-
form HIV viral load which could be used to correlate
virological failure and HPV infection. In addition some
important information such as tobacco use and informa-
tion for those who declined were not collected. However
the study established HPV prevalence and genotypes
distribution among HIV infected women.
Conclusion
In present study, HIV seropositive women with low CD4
counts and various grades of cervical SIL are signifi-
cantly infected with HR HPV genotypes. In countries
where HIV is endemic the governments should consider
addition of HPV vaccine in national immunization
programme focusing on epidemiology of HPV genotypes.
Data on the efficacy of the current vaccine in preventing
SIL/cancer and warts are highly needed in developing
countries for appropriate policy decision making.
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